CAR-T在甲状腺癌免疫治疗中的研究进展

Research progress of CAR-T therapy in the management of thyroid cancer

大多数甲状腺癌患者进行以外科治疗为主的综合治疗可以取得良好的预后,但目前晚期甲状腺癌治疗手段匮乏。采用体外基因编辑技术的嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)免疫疗法在血液系统肿瘤中得到应用并取得了良好的治疗效果。以此为基础,CAR-T开始在实体肿瘤中尝试使用,但效果欠佳。CAR-T在晚期甲状腺癌中的研究已有开展,目前仍局限在临床前的基础研究,相关临床试验较少且缺乏试验结果报道。本文将相关报道进行综述,旨在为今后的研究提供参考。

The majority of patients with thyroid cancer can attain a favorable prognosis following surgery;however,this is not the case for advanced thyroid cancer.Chimeric antigen receptor T-cell(CAR-T)immunotherapy has demonstrated successful outcomes in hematological tumors.Building upon this success,researchers have explored the application of CAR-T therapy in solid tumors,yet the results have been less than optimal.Although research into CAR-T for advanced thyroid cancer is underway,it remains primarily in the realm of basic research,with limited clinical trials and inconclusive outcomes.In this review,we examine pertinent reports to offer insights for future research endeavors.